ChromaDex Corp study report

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson’s Disease (PD) Building on a growing body of research showcasing NR … Read More

0
1 2 3 4 5 6 7 … 24